RESOURCE OVERVIEW
With the advent of more product niches and often lowered production quantities, facilities that are experienced and versatile in handling cytotoxic, highly potent, and non-cytotoxic oncology products can present a valid option when considering outsourcing. Risks for cross-contamination must be properly assessed, using state-of-the-art organization procedures, technical standards, and current industry guidance. Ultimately, patient safety is, as always, the driving force.
In this whitepaper learn more from the Simtra BioPharma Solutions team on the considerations for Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility.